Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR
Open Access
- 1 May 2000
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 14 (5) , 557-560
- https://doi.org/10.1046/j.1365-2036.2000.00738.x
Abstract
Background: Octreotide long acting repeteable (LAR) is a new somatostatin analogue whose activity lasts 28 days. Aim: To assess its therapeutic efficacy, tolerability, and safety in patients with ...Keywords
This publication has 10 references indexed in Scilit:
- Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: Future outlookAnnals of Oncology, 1999
- Octreotide Acetate Long-Acting Formulation Versus Open-Label Subcutaneous Octreotide Acetate in Malignant Carcinoid SyndromeJournal of Clinical Oncology, 1999
- Slow-Release Lanreotide Treatment in Endocrine Gastrointestinal TumorsAmerican Journal of Gastroenterology, 1998
- Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients.Gut, 1996
- Use of octreotide acetate for control of symptoms in patients with islet cell tumorsWorld Journal of Surgery, 1993
- Long-Term Management of the Carcinoid Syndrome Treatment with octreotide alone and in combination with alpha-interferonActa Oncologica, 1993
- An Update of the Medical Treatment of Malignant Endocrine Pancreatic TumorsActa Oncologica, 1993
- Somatostatin and Somatostatin Analogue (SMS 201-995) in Treatment of Hormone-Secreting Tumors of the Pituitary and Gastrointestinal Tract and Non-Neoplastic Diseases of the GutAnnals of Internal Medicine, 1989
- Clinical and hormonal effects of a long-acting somatostatin analogue in pancreatic endocrine tumors and in carcinoid syndromeCancer, 1987
- Treatment of the Malignant Carcinoid SyndromeNew England Journal of Medicine, 1986